Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy-Reference-Cited by-同舟云学术

Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy

Published:2021-11 Issue: Volume:157 Page:93-101
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Tully Karl H.,Jütte Hendrik,Wirtz Ralph M.,Jarczyk Jonas,Santiago-Walker Ademi,Zengerling Friedemann,Breyer Johannes,Sikic Danijel,Kriegmair Maximilian C.,von Hardenberg Jost,Wullich Bernd,Taubert Helge,Weyerer Veronika,Stoehr Robert,Bolenz Christian,Burger Maximilian,Porubsky Stefan,Hartmann Arndt,Roghmann Florian,Erben Philipp,Eckstein Markus

Funder

Janssen Pharmaceuticals

Janssen Research and Development LLC

Publisher

Elsevier BV

Subject

Urology

Reference29 articles.

1. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005

2. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract;Bellmunt;J Clin Oncol,2009

3. Oncology meets immunology: the cancer-immunity cycle;Chen;Immunity,2013

4. Mutational landscape and significance across 12 major cancer types;Kandoth;Nature,2013

5. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder;Guancial;Cancer Med,2014

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population;Clinical Genitourinary Cancer;2024-07

2. PD-L1 ( CD274 ) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma;OncoImmunology;2023-10-19

3. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment;Journal for ImmunoTherapy of Cancer;2023-09

4. E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies;Frontiers in Immunology;2023-07-11

5. Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases;Frontiers in Oncology;2023-04-14